Samuel K. Ackerman
Vorstandsvorsitzender bei Cyclis Pharmaceuticals, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Chyi-Shan Suen | M | - |
Vitex Systems, Inc.
| 15 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| John R. Barr | M | 67 |
V.I. Technologies, Inc.
 V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | 8 Jahre |
| Peyton J. Marshall | M | 69 | 2 Jahre | |
| Frederick Schmid | M | 67 | 2 Jahre | |
| David Tendler | M | - |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| Herb H. Hooper | M | 60 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| Doros Platika | M | - |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| John Richards | M | 67 | 3 Jahre | |
| Eric Linsley | M | 62 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| R. Fletcher | M | 78 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| John R. Chapman | M | 70 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | 6 Jahre |
| Kurt J. W. Andrews | M | 54 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 12 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Samuel K. Ackerman
- Persönliches Netzwerk
